These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 30478423)

  • 1.
    Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE
    Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probody Therapeutic Design of
    Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
    Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical PET imaging with the novel human antibody
    Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
    Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR
    Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging PD-L1 Expression with ImmunoPET.
    Truillet C; Oh HLJ; Yeo SP; Lee CY; Huynh LT; Wei J; Parker MFL; Blakely C; Sevillano N; Wang YH; Shen YS; Olivas V; Jami KM; Moroz A; Jego B; Jaumain E; Fong L; Craik CS; Chang AJ; Bivona TG; Wang CI; Evans MJ
    Bioconjug Chem; 2018 Jan; 29(1):96-103. PubMed ID: 29125731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with
    Ehlerding EB; Lee HJ; Barnhart TE; Jiang D; Kang L; McNeel DG; Engle JW; Cai W
    Bioconjug Chem; 2019 May; 30(5):1434-1441. PubMed ID: 30973703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
    Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
    Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Preclinical Assessment of
    Moroz A; Lee CY; Wang YH; Hsiao JC; Sevillano N; Truillet C; Craik CS; Fong L; Wang CI; Evans MJ
    Bioconjug Chem; 2018 Oct; 29(10):3476-3482. PubMed ID: 30227708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.